Clinical Trial Update: Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a predictive model for response to Romiplostim in patients with IPSS low or intermediate-1 risk myelodysplastic syndromes an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Romiplostim (romiplostim)

Snippet

Sponsor: Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2023-07-14